NextPoint Therapeutics Announces IND Clearance from the FDA to …
Dec 9, 2023 · NPX887, a monoclonal antibody targeting HHLA2, is designed to enhance immune responses in the tumor microenvironment. CAMBRIDGE, MA, USA I December 07, 2023 I NextPoint Therapeutics, a clinical-stage biotechnology company developing precision immuno-oncology therapeutics targeting the novel HHLA2 pathway, today announced the acceptance of its investigational new drug (IND) application by the U ...
Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel ...
Oct 25, 2023 · The Phase 2 clinical trial will assess the safety and efficacy of ZYIL1 in Amyotrophic Lateral Sclerosis (ALS) patients [ClinicalTrials.gov ID: NCT05981040]
All news - Pipelinereview
Nov 6, 2024 · Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, CA, USA and NANJING, China I November 7, 2024 I Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreement to develop LBL-051, […]
PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
FDA Approves IMULDOSA® (ustekinumab-srlf), Accord …
Oct 14, 2024 · With the approval of IMULDOSA, Accord BioPharma's biosimilar portfolio continues to grow while expanding treatment options appropriate for patients
Horizon Therapeutics plc Announces First Subject Dosed in Phase …
DUBLIN, Ireland I December 08, 2022 I Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first subject has been dosed in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its development-stage medicine HZN-457, previously known as ARO-XDH. HZN-457 is a small interfering RNA (siRNA) candidate designed to treat ...
PeptiDream and Takeda Expand Collaborative Research and …
Jul 28, 2021 · – Expansion of existing partnership covering neuromuscular indications to now include CNS indications in neurodegeneration – PeptiDream is eligible to receive up to approximately $3.5 billion in total, as upfront and potential preclinical / clinical / launch / sales-based milestones, excluding royalty payments
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live ...
Jan 21, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
ARTBIO and PharmaLogic Announce Supply Agreement for Lead …
Jan 12, 2024 · CAMBRIDGE, MA and BOCA RATON, FL, USA I January 12, 2024 I PharmaLogic Holdings Corp. (“PharmaLogic”), a leading radiopharmaceutical contract development and manufacturing organization, and ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs), today announce a manufacturing and supply agreement for ARTBIO’s lead-212 (212 Pb ...
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
Jan 25, 2022 · The Phase 1, randomized, double-blind, placebo-controlled trial will assess the safety, tolerability and pharmacokinetics of escalating single and multiple doses of CVN766 in healthy subjects. The company expects to complete the Phase 1 study by year-end. Cerevance is continuing to actively enroll patients in the Phase 1 study.